Post by icemandios on Feb 6, 2024 13:50:04 GMT
Aspira Women’s Health Announces OvaSuite(SM) Distribution Agreement in the Philippines
AUSTIN, Texas, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the signing of a 5-year distribution agreement granting Hi-Precision Laboratories the exclusive right to market and distribute the OvaSuite SM portfolio in the Philippines. The commercialization of OvaSuite products in the Philippines will commence upon receiving approval from the local regulatory authority. In consideration of the licenses and rights granted by Aspira, Hi-Precision Laboratories will pay royalties to Aspira for each test performed in the Philippines.
“We are thrilled to partner with one of the largest medical laboratories in the Philippines, an important step towards achieving our goal to make OvaSuite available worldwide,” said Nicole Sandford, President and Chief Executive Officer of Aspira. “Moreover, the Clinical Performance of a Multivariate Index Assay in Detecting Early-Stage Ovarian Cancer in Filipino Women study clearly demonstrated improvements in the detection of early-stage ovarian cancers when an Aspira test was incorporated in the clinical assessment of women presenting with an ovarian mass.”
Vannessa Ongsue, Vice President, Medical Services at Hi-Precision Laboratories stated, “Hi-Precision is excited to make the OvaSuite portfolio available to women and clinicians in the Philippines as research has suggested that women in the Philippines have a higher risk of ovarian cancer than in other parts of the world. Aspira’s blood tests are very valuable tools for clinicians that will lead to a higher standard of care for women in the Philippines.”
Hi-Precision Laboratories, the largest medical laboratory in the Philippines, provides a wide array of services from routine to esoteric specialty tests and is internationally certified and accredited by the Philippine Accreditation Bureau. With branches nationwide, Hi-Precision Laboratories conducted 79 million tests between 2014 and 2022 and has consistently received recognition as a top-quality service provider in the Philippines.
About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.
OvaWatch SM and Ova1Plus ® are offered to clinicians as OvaSuite SM . Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of 99% and is used to assess ovarian cancer risk for women where initial clinical assessment indicates the mass is indeterminate or benign, and thus surgery may be premature or unnecessary. Ova1Plus is comprised of two FDA-cleared tests, Ova1 ® and Overa ® , to assess the risk of ovarian malignancy in women planned for surgery.
Our in-development test pipeline is designed to expand our ovarian cancer portfolio and addresses the tremendous need for noninvasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, our OvaMDx test is designed to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, EndoCheck SM is the first-ever noninvasive test designed to identify endometriomas, one of the most commonly occurring forms of endometriosis. The EndoMDx SM test is designed to combine microRNA and protein biomarkers with patient data to identify all endometriosis.